Atrial Fibrillation
Friday, August 30th, 2013
CIRCEP: August 29, 2013 Background—Magnetic resonance imaging (MRI)-detected brain lesions are common following left atrial catheter ablation (LACA) for symptomatic atrial fibrillation. The clinical relevance of these acute ischemic lesions is not fully understood, but ablation-related cerebral injury could contribute to cognitive dysfunction. Methods and Results—In the prospective “Mesh Ablator versus Cryoballoon Pulmonary Vein Ablation of […]
Atrial Fibrillation
Friday, August 30th, 2013
Europace: August 27, 2013 The management of atrial fibrillation (AF) has seen marked changes in past years, with the introduction of new oral anticoagulants, new antiarrhythmic drugs, and the emergence of catheter ablation as a common intervention for rhythm control. Furthermore, new technologies enhance our ability to detect AF. Most clinical management decisions in AF patients […]
Atrial Fibrillation
Friday, August 30th, 2013
STROKEAHA: August 27, 2013 Background and Purpose—Atrial fibrillation (AF) is a major risk factor for ischemic stroke. This study aims to update the knowledge about AF and associated stroke risk and benefits of anticoagulation. Methods—We extracted data from the hospital, specialized outpatient, and primary healthcare and drug registries in a Swedish region with 1.56 million residents. […]
Atrial Fibrillation
Friday, August 30th, 2013
CIRCEP: August 27, 2013 Background—Identification of critical atrial substrates in nonparoxysmal atrial fibrillation (AF) patients failing to respond to pulmonary vein isolation (PVI) is important. This study investigated the signal characteristics, substrate nature, and ablation results of rotors during AF. Methods and Results—In total 53 patients (age=55±8), 31 with persistent AF and 22 with long-lasting […]
Atrial Fibrillation
Friday, August 30th, 2013
CIRCEP: August 27, 2013 Background—This prospective, multi-center study sought to evaluate the incidence of asymptomatic cerebral embolism (ACE) during ablation of atrial fibrillation (AF) using a multi-electrode radiofrequency (MER) system when specific procedural changes were applied. Methods and Results—Sixty subjects (age 60±10 years, 87% paroxysmal, CHADS2 score 0.6±0.7) undergoing AF ablation with a circular MER catheter […]
Clinical Trials
Friday, August 30th, 2013
STROKEAHA: 7/29/13 Background and Purpose—To investigate the association of low estimated glomerular filtration rate (eGFR) <60 mL/min with recurrent stroke risk and to evaluate whether add-on renin–angiotensin system modulator therapy is associated with lower recurrent stroke risk in patients with low eGFR. Methods—We analyzed the database of a multicenter trial involving 18 666 patients with […]
Clinical Trials
Friday, August 30th, 2013
Implementation Science: August 23, 2013 Medical Research Council (MRC) guidance identifies implementation as a key element of the development and evaluation process for complex healthcare interventions. Implementation is itself a complex process involving the mobilization of human, material, and organizational resources to change practice within settings that have pre-existing structures, historical patterns of relationships, and routinized […]
Clinical Trials
Friday, August 30th, 2013
J Am Heart Assoc: August 20, 2013 Background The purpose of this study was to determine whether interventions including components to improve adherence to antihypertensive medications in patients after stroke/transient ischemic attack (TIA) improve adherence and blood pressure control. Methods and Results We searched MEDLINE, EMBASE, CINAHL, BNI, PsycINFO, and article reference lists to October 2012. Search terms […]
Clinical Trials
Friday, August 30th, 2013
STROKEAHA: 7/18/13 A Meta-analysis of Patent Foramen Ovale Closure Trials Until recently, the evidence base for patent foramen ovale (PFO) closure with a device to prevent future cerebrovascular events in patients with cryptogenic stroke and presumed paradoxical embolism consisted of a large body of >50 observational studies that cumulatively showed substantial and unequivocal benefits with […]
Clinical Trials
Friday, August 30th, 2013
STROKEAHA: 7/18/13 Background and Purpose—Minocycline, in animal models and 2 small randomized controlled human trials, is a promising neuroprotective agent in acute stroke. We analyzed the efficacy and safety of intravenous minocycline in acute ischemic and hemorrhagic stroke. Methods—A multicenter prospective randomized open-label blinded end point evaluation pilot study of minocycline 100 mg administered intravenously, commenced […]
